German Biotech Clears Phase I with New Gene Therapy for Glaucoma – Labiotech.eu (blog)
|
German Biotech Clears Phase I with New Gene Therapy for Glaucoma
Labiotech.eu (blog) Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic … |
